Stock Traders Purchase High Volume of Zentalis Pharmaceuticals Call Options (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the target of unusually large options trading activity on Monday. Investors purchased 3,891 call options on the stock. This represents an increase of approximately 5,886% compared to the typical daily volume of 65 call options.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $3.68 on Tuesday. Zentalis Pharmaceuticals has a fifty-two week low of $2.83 and a fifty-two week high of $23.52. The firm’s fifty day moving average price is $3.54 and its two-hundred day moving average price is $8.62. The company has a market capitalization of $261.38 million, a P/E ratio of -1.11 and a beta of 1.70.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same quarter in the prior year, the business posted ($1.85) EPS. On average, equities research analysts expect that Zentalis Pharmaceuticals will post -2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus lowered their price objective on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, June 18th. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective on the stock in a research note on Monday, August 12th. Jefferies Financial Group restated a “hold” rating and issued a $6.00 price objective (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a research note on Tuesday, June 18th. UBS Group downgraded shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $28.00 to $5.00 in a research note on Thursday, June 20th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $8.00 price objective (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research note on Tuesday, June 18th. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $10.78.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ZNTL. Eventide Asset Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 47.9% in the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after purchasing an additional 3,745,936 shares in the last quarter. Decheng Capital LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at about $31,809,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after buying an additional 585,644 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after buying an additional 399,745 shares during the last quarter. Finally, Opaleye Management Inc. bought a new position in shares of Zentalis Pharmaceuticals in the first quarter valued at about $3,152,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.